Ro is not a pharmaceutical manufacturer like Novo Nordisk or Eli Lilly. It is a digital healthcare and telehealth company that connects patients with clinicians, prescriptions, pharmacies and ongoing care.
Its strongest position in diabetes and obesity is therefore indirect. Ro does not need to discover the next GLP-1 drug to benefit from the category. Instead, it can compete for the patient relationship, prescription journey, treatment support and recurring subscription revenue around medicines developed by pharmaceutical companies.
This makes indirect competitor monitoring particularly important for Ro.
Where Ro Sits in the Competitive Chain
Ro’s Body program provides access to GLP-1 medications when clinically appropriate, together with ongoing clinical support and tools designed to support long-term weight management. (ro.co)
The company has also built relationships with the pharmaceutical companies producing the leading medicines.
Ro partnered with Eli Lilly to offer Zepbound through LillyDirect and later integrated with Novo Nordisk to provide Wegovy through its platform. In January 2026, Ro also became one of the telehealth platforms offering the newly launched Wegovy pill.
This creates an interesting competitive model.
Ro competes indirectly with other patient-access platforms such as Hims & Hers, Noom and WeightWatchers, while simultaneously depending on pharmaceutical companies such as Novo Nordisk and Eli Lilly for the medicines that attract many patients.
The Real Competitors Are Not Just Other Telehealth Companies
For Ro, competitor monitoring needs to cover several layers.
Novo Nordisk and Eli Lilly are upstream competitors for patient relationships because both increasingly provide direct access to their medicines and patient-support services.
Hims & Hers is a much closer digital competitor because it combines online clinical consultations, prescriptions and subscription-based care. Reuters reported that weight-loss offerings already represented roughly one-third of Hims & Hers’ revenue in 2026.
Noom competes through digital behavior-change and weight-management programs, while WeightWatchers has expanded into prescription weight-management services.
For Ro, the competitive question is therefore not simply, “Who sells the same medicine?” It is:
Who controls the patient before, during and after the prescription?
Ro’s Commercial Scale Is Growing, but Exact Revenue Is Private
Ro is privately held and does not publish audited revenue in the same way as publicly traded pharmaceutical companies.
Third-party estimates provide some indication of its scale. Sacra estimates that Ro generated approximately $370 million in GLP-1 revenue during 2024, including care subscriptions and pharmacy economics. This is an estimate rather than company-reported audited revenue.
Ro’s commercial momentum has also been visible through its recent GLP-1 expansion.
In January 2026, CEO Zach Reitano said the Wegovy pill launch was bringing new customers to the platform, including men who had previously avoided injectable treatments. The introductory price was $149 per month for the lowest dose, with higher doses reaching $299.
Not sure where to focus next? Our experts help you identify the right companies, regions, investments, and strategies for your business. Download customized sample: https://www.towardshealthcare.com/download-sample/5341
Competitive Snapshot
| Company | Role | Key 2025–26 indicator |
|---|---|---|
| Ro | Telehealth & medication access | $370M estimated GLP-1 revenue in 2024 |
| Hims & Hers | Telehealth & subscriptions | $2.89B projected 2026 revenue |
| Novo Nordisk | GLP-1 manufacturer | Wegovy + Ozempic franchise |
| Eli Lilly | GLP-1 manufacturer | Zepbound + Mounjaro franchise |
| Noom | Digital weight management | Competes for digital patient engagement |
Ro’s figure is an independent estimate, while the Hims & Hers figure is an analyst projection reported by Reuters, so these numbers should not be interpreted as directly comparable audited revenues.
Why Indirect Competitor Monitoring Matters More for Ro
Ro’s economics can change rapidly when pharmaceutical companies change pricing, supply, distribution or patient-access policies.
The launch of oral GLP-1 medicines is a good example. The Wegovy pill gives patients an alternative to injections and potentially expands the addressable patient pool.
At the same time, pharmaceutical companies are building their own direct-to-consumer channels. This could eventually reduce the amount of value captured by intermediary platforms.
That is why Ro needs to monitor manufacturer-owned platforms, drug pricing, insurance coverage, pharmacy partnerships, telehealth competitors and new oral medicines rather than only watching companies with similar websites.
Partnerships Are Becoming a Competitive Weapon
Ro’s relationship with pharmaceutical companies is one of its most important strategic assets.
In January 2026, Ro partnered with Amgen to study barriers to obesity-treatment access, including insurance coverage and prior-authorization requirements for GLP-1 therapies. The collaboration is intended to use data from Ro’s platform to understand where patients encounter access problems.
This is strategically important because Ro can provide something pharmaceutical companies do not naturally possess at the same scale: direct insight into the patient journey.
Data around prescriptions, insurance approvals, treatment initiation and patient engagement can help identify where patients drop out of the treatment pathway.
The Biggest Competitive Risk
The largest risk is not necessarily another telehealth startup.
It is disintermediation.
If Novo Nordisk, Eli Lilly and other pharmaceutical companies increasingly provide medication, clinical support, affordability programs and patient services directly, Ro could face pressure on margins and customer ownership.
There is also competition from lower-cost providers. Reuters reported that some employers are considering dropping coverage for expensive weight-loss medicines, potentially pushing patients toward direct-to-consumer platforms.
Ro therefore needs to prove that its clinical experience, technology, convenience and patient retention are valuable enough for users and pharmaceutical partners to keep using the platform.
Where Should We Invest?
The strongest opportunity is not simply another GLP-1 prescription website.
We would prioritize companies building infrastructure around the treatment journey.
| Investment area | Priority | What to look for |
| GLP-1 patient-management platforms | High | Retention and recurring revenue |
| Insurance & prior-authorization technology | High | Faster approvals and lower abandonment |
| Medication adherence technology | High | Long-term patient engagement |
| Nutrition + GLP-1 platforms | High | Integrated lifestyle support |
| Diabetes monitoring & CGM integration | High | Real-time clinical data |
| Pharmacy/telehealth infrastructure | Medium-High | Strong provider and pharma connections |
| Generic telehealth clinics | Medium-Low | Differentiation and pricing power |
The most attractive opportunity is where medication + clinical care + nutrition + monitoring + insurance navigation come together.
Genuine Opinion
Ro has a strong strategic position because it sits between patients, physicians, pharmacies and pharmaceutical companies. Its partnership model gives it access to major therapies without having to spend billions developing them.
However, this also creates its biggest weakness: Ro does not own the blockbuster medicines driving much of the demand.
Our view is that Ro’s long-term value will depend on whether it becomes more than a prescription intermediary. The stronger business would be a full digital obesity-care platform that owns the patient relationship, improves adherence, manages nutrition and lifestyle, supports insurance navigation and provides useful real-world data to pharmaceutical partners.
For leaders evaluating Ro or similar companies, the most important indicators to monitor are monthly active patients, prescription conversion, GLP-1 retention, recurring subscription revenue, medication margins, customer acquisition cost, insurance approval rates, pharmaceutical partnerships and the percentage of patients who remain on the platform after starting treatment.
That is where indirect competitor monitoring becomes valuable: the biggest threat to Ro may come not from another Ro-like company, but from a pharmaceutical manufacturer, pharmacy or technology platform that gradually takes control of the same patient journey.
Important Links
Get a customized dashboard built around your niche; with the exact data and insights you need. Request for a demo: https://www.towardshealthcare.com/access-dashboard
About Us
Healthcare WebWire is a part of Towards Healthcare Research & Consulting is a global healthcare market research and consulting firm dedicated to helping businesses make informed decisions through reliable market intelligence and strategic insights. We serve pharmaceutical, biotechnology, medical device, AI in healthcare, cell and gene therapy, digital health, and life sciences organizations with in-depth market research, custom consulting, competitive analysis, and growth forecasts. Our team combines industry expertise with rigorous research to deliver clear, actionable insights that support market expansion, product strategy, investment decisions, and long-term business growth. From emerging innovations to established healthcare markets, we help organizations understand where the industry is today and where it’s headed tomorrow.
Connect with us for more enquiry at [email protected]
Europe Region – +44 778 256 0738
North America Region – +1 8044 4193 44
APAC Region: +91 9356 9282 04
Visit Our Website: https://www.towardshealthcare.com
Find us on social platforms: LinkedIn | Twitter | Instagram | Medium